Pharmacokinetics of drugs in adult living donor liver transplant patients: regulatory factors and observations based on studies in animals and humans

References

• Starzl TE, Groth CG, Brettschneider L, et al. Orthotopic homotransplantation of the human liver. Ann Surg. 1968;168(3):392–415.
   PubMed Web of Science ®Google Scholar
• Starzl TE, Fung JJ. Themes of liver transplantation. Hepatology. 2010;51(6):1869–84.
   PubMed Web of Science ®Google Scholar
• Strong RW, Lynch SV, Ong TH, et al. Successful liver transplantation from a living donor to her son. N Engl J Med. 1990;322(21):1505–1507.
   PubMed Web of Science ®Google Scholar
• Carlisle EM, Testa G. Adult to adult living related liver transplantation: where do we currently stand? World J Gastroenterol. 2012;18(46):6729–6736.
   PubMed Web of Science ®Google Scholar
• Saidi RF. Current status of liver transplantation. Arch Iran Med. 2012;15(12):772–776.
   PubMed Web of Science ®Google Scholar
• Pomfret EA, Fryer JP, Sima CS, et al. Liver and intestine transplantation in the United States, 1996-2005. Am J Transplant. 2007;7(5 Pt 2):1376–1389.
   PubMed Web of Science ®Google Scholar
• Kulik L, Abecassis M. Living donor liver transplantation for hepatocellular carcinoma. Gastroenterology. 2004;127(5 Suppl 1):S277–82.
   PubMedGoogle Scholar
• Shukla A, Vadeyar H, Rela M, et al. Liver transplantation: East versus West. J Clin Exp Hepatol. 2013;3(3):243–253.
   PubMedGoogle Scholar
• Hori T, Iida T, Yagi S, et al. K(ICG) value, a reliable real-time estimator of graft function, accurately predicts outcomes in adult living-donor liver transplantation. Liver Transpl. 2006;12(4):605–613.
   PubMed Web of Science ®Google Scholar
• Wrighton LJ, O’Bosky KR, Namm JP, et al. Postoperative management after hepatic resection. J Gastrointest Oncol. 2012;3(1):41–47.
   PubMedGoogle Scholar
• Masuda S, Goto M, Kiuchi T, et al. Enhanced expression of enterocyte P-glycoprotein depresses cyclosporine bioavailability in a recipient of living donor liver transplantation. Liver Transpl. 2003;9(10):1108–1113.
   PubMed Web of Science ®Google Scholar
• Mukhtar A,A,ELM, Moniem AA, et al. The impact of maintaining normal serum albumin level following living related liver transplantation: does serum albumin level affect the course? A Pilot Study. Transplant Proc. 2007;39(10):3214–3218.
   PubMed Web of Science ®Google Scholar
• Huang ML, Venkataramanan R, Burckart GJ, et al. Drug-binding proteins in liver transplant patients. J Clin Pharmacol. 1988;28(6):505–506.
   PubMedGoogle Scholar
• Florman S, Miller CM. Live donor liver transplantation. Liver Transpl. 2006;12(4):499–510.
   PubMed Web of Science ®Google Scholar
• Raut V, Alikhanov R, Belghiti J, et al. Review of the surgical approach to prevent small-for-size syndrome in recipients after left lobe adult LDLT. Surg Today. 2014;44(7):1189–1196.
   PubMed Web of Science ®Google Scholar
• Dahm F, Georgiev P, Clavien PA. Small-for-size syndrome after partial liver transplantation: definition, mechanisms of disease and clinical implications. Am J Transplant. 2005;5(11):2605–2610.
   PubMed Web of Science ®Google Scholar
• Kelly DM, Miller C. Understanding the splenic contribution to portal flow: the role of splenic artery ligation as inflow modification in living donor liver transplantation. Liver Transpl. 2006;12(8):1186–1188.
   PubMed Web of Science ®Google Scholar
• Everson GT, Hoefs JC, Niemann CU, et al. Functional elements associated with hepatic regeneration in living donors after right hepatic lobectomy. Liver Transpl. 2013;19(3):292–304.
   PubMed Web of Science ®Google Scholar
• Schindl MJ, Redhead DN, Fearon KC, et al. The value of residual liver volume as a predictor of hepatic dysfunction and infection after major liver resection. Gut. 2005;54(2):289–296.
   PubMed Web of Science ®Google Scholar
• Serenari M, Cescon M, Cucchetti A, et al. Liver function impairment in liver transplantation and after extended hepatectomy. World J Gastroenterol. 2013;19(44):7922–7929.
   PubMed Web of Science ®Google Scholar
• Fausto N, Campbell JS, Riehle KJ. Liver regeneration. Hepatology. 2006;43(2 Suppl 1):S45–53.
   PubMed Web of Science ®Google Scholar
• Haga J, Shimazu M, Wakabayashi G, et al. Liver regeneration in donors and adult recipients after living donor liver transplantation. Liver Transpl. 2008;14(12):1718–24.
   PubMed Web of Science ®Google Scholar
• Chiu KW, Nakano T, Chen KD, et al. Cytochrome P450 in living donor liver transplantation. J Biomed Sci. 2015;22:32.
   PubMed Web of Science ®Google Scholar
• Ishizuka M, Yoshino S, Yamamoto Y, et al. Isozyme selective alterations of the expression of cytochrome P450 during regeneration of male rat liver following partial hepatectomy. Xenobiotica. 1997;27(9):923–931.
   PubMed Web of Science ®Google Scholar
• Trautwein C, Rakemann T, Obermayer-Straub P, et al. Differences in the regulation of cytochrome P450 family members during liver regeneration. J Hepatol. 1997;26(1):48–54.
   PubMed Web of Science ®Google Scholar
• Pellizzer AM, Smid SA, Strasser SI, et al. UDP-glucuronosyltransferase in the regenerating rat liver. J Gastroenterol Hepatol. 1996;11(12):1130–1136.
   PubMed Web of Science ®Google Scholar
• Tamasi V, Kiss A, Dobozy O, et al. The effect of dexamethasone on P450 activities in regenerating rat liver. Biochem Biophys Res Commun. 2001;286(2):239–242.
   PubMed Web of Science ®Google Scholar
• Tian H, Ou J, Strom SC, et al. Activity and expression of various isoforms of uridine diphosphate glucuronosyltransferase are differentially regulated during hepatic regeneration in rats. Pharm Res. 2005;22(12):2007–15.
   PubMed Web of Science ®Google Scholar
• Henderson PT, Kersten KJ. Metabolism of drugs during rat liver regeneration. Biochem Pharmacol. 1970;19(7):2343–2351.
   PubMed Web of Science ®Google Scholar
• Vos TA, Ros JE, Havinga R, et al. Regulation of hepatic transport systems involved in bile secretion during liver regeneration in rats. Hepatology. 1999;29(6):1833–1839.
   PubMed Web of Science ®Google Scholar
• Dransfeld O, Gehrmann T, Kohrer K, et al. Oligonucleotide microarray analysis of differential transporter regulation in the regenerating rat liver. Liver Int. 2005;25(6):1243–1258.
   PubMed Web of Science ®Google Scholar
• Gerloff T, Geier A, Stieger B, et al. Differential expression of basolateral and canalicular organic anion transporters during regeneration of rat liver. Gastroenterology. 1999;117(6):1408–1415.
   PubMed Web of Science ®Google Scholar
• Chang TH, Hakamada K, Toyoki Y, et al. Expression of MRP2 and MRP3 during liver regeneration after 90% partial hepatectomy in rats. Transplantation. 2004;77(1):22–27.
   PubMed Web of Science ®Google Scholar
• Kimura N, Hakamada K, Ikenaga SK, et al. Gene expression of ATP-binding cassette transporters during liver regeneration after 90% hepatectomy in rats. Int J Mol Med. 2012;30(1):28–34.
   PubMed Web of Science ®Google Scholar
• Geier A, Wagner M, Dietrich CG, et al. Principles of hepatic organic anion transporter regulation during cholestasis, inflammation and liver regeneration. Biochim Biophys Acta. 2007;1773(3):283–308.
   PubMed Web of Science ®Google Scholar
• Teeter LD, Estes M, Chan JY, et al. Activation of distinct multidrug-resistance (P-glycoprotein) genes during rat liver regeneration and hepatocarcinogenesis. Mol Carcinog. 1993;8(2):67–73.
   PubMed Web of Science ®Google Scholar
• Zhuang Y, de Vries DE, Xu Z, et al. Evaluation of disease-mediated therapeutic protein-drug interactions between an anti-interleukin-6 monoclonal antibody (sirukumab) and cytochrome P450 activities in a phase 1 study in patients with rheumatoid arthritis using a cocktail approach. J Clin Pharmacol. 2015;55(12):1386–1394.
   PubMed Web of Science ®Google Scholar
• Morgan ET, Thomas KB, Swanson R, et al. Selective suppression of cytochrome P-450 gene expression by interleukins 1 and 6 in rat liver. Biochim Biophys Acta. 1994;1219(2):475–483.
   PubMed Web of Science ®Google Scholar
• Nadin L, Butler AM, Farrell GC, et al. Pretranslational down-regulation of cytochromes P450 2C11 and 3A2 in male rat liver by tumor necrosis factor alpha. Gastroenterology. 1995;109(1):198–205.
   PubMed Web of Science ®Google Scholar
• Abdel-Razzak Z, Loyer P, Fautrel A, et al. Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture. Mol Pharmacol. 1993;44(4):707–715.
   PubMed Web of Science ®Google Scholar
• Geier A, Dietrich CG, Voigt S, et al. Cytokine-dependent regulation of hepatic organic anion transporter gene transactivators in mouse liver. Am J Physiol Gastrointest Liver Physiol. 2005;289(5):G831–41.
   PubMed Web of Science ®Google Scholar
• Siewert E, Dietrich CG, Lammert F, et al. Interleukin-6 regulates hepatic transporters during acute-phase response. Biochem Biophys Res Commun. 2004;322(1):232–238.
   PubMed Web of Science ®Google Scholar
• Le Vee M, Lecureur V, Stieger B, et al. Regulation of drug transporter expression in human hepatocytes exposed to the proinflammatory cytokines tumor necrosis factor-alpha or interleukin-6. Drug Metab Dispos. 2009;37(3):685–693.
   PubMed Web of Science ®Google Scholar
• Le Vee M, Gripon P, Stieger B, et al. Down-regulation of organic anion transporter expression in human hepatocytes exposed to the proinflammatory cytokine interleukin 1beta. Drug Metab Dispos. 2008;36(2):217–222.
   PubMed Web of Science ®Google Scholar
• Morgan ET. Regulation of cytochrome p450 by inflammatory mediators: why and how? Drug Metab Dispos. 2001;29(3):207–212.
   PubMed Web of Science ®Google Scholar
• Morgan ET, Li-Masters T, Cheng PY. Mechanisms of cytochrome P450 regulation by inflammatory mediators. Toxicology. 2002;181–182:207–210.
   PubMed Web of Science ®Google Scholar
• Morales-Gonzalez JA, Gutierrez-Salinas J, Hernandez-Munoz R. Pharmacokinetics of the ethanol bioavailability in the regenerating rat liver induced by partial hepatectomy. Alcohol Clin Exp Res. 1998;22(7):1557–1563.
   PubMed Web of Science ®Google Scholar
• Al-Jahdari WS, Kunimoto F, Saito S, et al. Total body propofol clearance (TBPC) after living-donor liver transplantation (LDLT) surgery is decreased in patients with a long warm ischemic time. J Anesth. 2006;20(4):323–326.
   PubMedGoogle Scholar
• Friedman BH, Wolf JH, Wang L, et al. Serum cytokine profiles associated with early allograft dysfunction in patients undergoing liver transplantation. Liver Transpl. 2012;18(2):166–176.
   PubMed Web of Science ®Google Scholar
• Prima V, Cao M, Svetlov SI. ASS and SULT2A1 are novel and sensitive biomarkers of acute hepatic injury - a comparative study in animal models. J Liver. 2013;2:1.
   Google Scholar
• Neil DA, Hubscher SG. Current views on rejection pathology in liver transplantation. Transpl Int. 2010;23(10):971–983.
   PubMed Web of Science ®Google Scholar
• Choudhary NS, Saigal S, Shukla R, et al. Current status of immunosuppression in liver transplantation. J Clin Exp Hepatol. 2013;3(2):150–158.
   PubMedGoogle Scholar
• Goto M, Masuda S, Kiuchi T, et al. CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation. Pharmacogenetics. 2004;14(7):471–478.
   PubMedGoogle Scholar
• Hashida T, Masuda S, Uemoto S, et al. Pharmacokinetic and prognostic significance of intestinal MDR1 expression in recipients of living-donor liver transplantation. Clin Pharmacol Ther. 2001;69(5):308–316.
   PubMed Web of Science ®Google Scholar
• Ji E, Choi L, Suh KS, et al. Combinational effect of intestinal and hepatic CYP3A5 genotypes on tacrolimus pharmacokinetics in recipients of living donor liver transplantation. Transplantation. 2012;94(8):866–872.
   PubMed Web of Science ®Google Scholar
• Masuda S, Inui K. An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients. Pharmacol Ther. 2006;112(1):184–198.
   PubMed Web of Science ®Google Scholar
• Rojas LE, Herrero MJ, Boso V, et al. Meta-analysis and systematic review of the effect of the donor and recipient CYP3A5 6986A>G genotype on tacrolimus dose requirements in liver transplantation. Pharmacogenet Genomics. 2013;23(10):509–517.
   PubMed Web of Science ®Google Scholar
• Uesugi M, Hosokawa M, Shinke H, et al. Influence of cytochrome P450 (CYP) 3A4*1G polymorphism on the pharmacokinetics of tacrolimus, probability of acute cellular rejection, and mRNA expression level of CYP3A5 rather than CYP3A4 in living-donor liver transplant patients. Biol Pharm Bull. 2013;36(11):1814–1821.
   PubMed Web of Science ®Google Scholar
• Chiu KW, Nakano T, Chen KD, et al. Homogeneous phenomenon of the graft when using different genotype characteristic of recipients/donors in living donor liver transplantation. World J Hepatol. 2013;5(11):642–648.
   PubMedGoogle Scholar
• Chiu KW, Tai WC, Nakano T, et al. Donor graft does not affect the P450 2C19 genotype expressed in peripheral blood in recipients of living donor liver transplantation. Clin Transplant. 2010;24(6):830–834.
   PubMed Web of Science ®Google Scholar
• Chiu KW, Nakano T, Hu TH, et al. Homogenous phenomenon of graft liver CYP2C19 genotypes after living donor liver transplantation. Eur J Clin Invest. 2012;42(4):352–356.
   PubMed Web of Science ®Google Scholar
• Michalopoulos GK, DeFrances MC. Liver regeneration. Science. 1997;276(5309):60–6.
   PubMed Web of Science ®Google Scholar
• Tian H, Ou J, Strom SC, et al. Pharmacokinetics of tacrolimus and mycophenolic acid are altered, but recover at different times during hepatic regeneration in rats. Drug Metab Dispos. 2005;33(3):329–35.
   PubMed Web of Science ®Google Scholar
• Morine Y, Shimada M, Torii M, et al. Optimal administration of tacrolimus in reduced-size liver. Dig Dis Sci. 2009;54(8):1789–1793.
   PubMed Web of Science ®Google Scholar
• Lodewijk L, Mall A, Spearman CW, et al. Effect of liver regeneration on the pharmacokinetics of immunosuppressive drugs. Transplant Proc. 2009;41(1):379–381.
   PubMed Web of Science ®Google Scholar
• Murayama T, Sato Y, Wainai T, et al. Effect of continuous infusion of propofol on its concentration in blood with and without the liver in pigs. Transplant Proc. 2005;37(10):4567–4570.
   PubMed Web of Science ®Google Scholar
• Hiraoka H, Yamamoto K, Miyoshi S, et al. Kidneys contribute to the extrahepatic clearance of propofol in humans, but not lungs and brain. Br J Clin Pharmacol. 2005;60(2):176–182.
   PubMed Web of Science ®Google Scholar
• Maza A, Gascon AR, Calvo MB, et al. Influence of partial hepatectomy on theophylline pharmacokinetics in rats. J Pharm Sci. 1996;85(10):1133–1135.
   PubMed Web of Science ®Google Scholar
• Maza AM, Gascon AR, Hernandez RM, et al. Influence of hepatic regeneration after partial hepatectomy on theophylline pharmacokinetics in rats. Eur J Drug Metab Pharmacokinet. 2001;26(1–2):53–58.
   PubMed Web of Science ®Google Scholar
• Troisi R, Militerno G, Hoste E, et al. Are reduced tacrolimus dosages needed in the early postoperative period following living donor liver transplantation in adults?Transplant Proc. 2002;34(5):1531–1532.
   PubMed Web of Science ®Google Scholar
• Jain A, Venkataramanan R, Sharma R, et al. Pharmacokinetics of tacrolimus in living donor liver transplant and deceased donor liver transplant recipients. Transplantation. 2008;85(4):554–60.
   PubMed Web of Science ®Google Scholar
• Minematsu T, Sugiyama E, Kusama M, et al. Effect of hematocrit on pharmacokinetics of tacrolimus in adult living donor liver transplant recipients. Transplant Proc. 2004;36(5):1506–1511.
   PubMed Web of Science ®Google Scholar
• Fukatsu S, Yano I, Igarashi T, et al. Population pharmacokinetics of tacrolimus in adult recipients receiving living-donor liver transplantation. Eur J Clin Pharmacol. 2001;57(6–7):479–484.
   PubMed Web of Science ®Google Scholar
• Harihara Y, Sano K, Makuuchi M, et al. Correlation between graft size and necessary tacrolimus dose after living-related liver transplantation. Transplant Proc. 2000;32(7):2166–2167.
   PubMed Web of Science ®Google Scholar
• Sugawara Y, Makuuchi M, Kaneko J, et al. Correlation between optimal tacrolimus doses and the graft weight in living donor liver transplantation. Clin Transplant. 2002;16(2):102–106.
   PubMed Web of Science ®Google Scholar
• Gerard C, Stocco J, Hulin A, et al. Determination of the most influential sources of variability in tacrolimus trough blood concentrations in adult liver transplant recipients: a bottom-up approach. Aaps J. 2014;16(3):379–391.
   PubMed Web of Science ®Google Scholar
• Jain A, Venkataramanan R, Sharma R, et al. Pharmacokinetics of mycophenolic acid in live donor liver transplant patients vs deceased donor liver transplant patients. J Clin Pharmacol. 2008;48(5):547–52.
   PubMed Web of Science ®Google Scholar
• Shen B, Chen B, Zhang W, et al. Comparison of pharmacokinetics of mycophenolic acid and its metabolites between living donor liver transplant recipients and deceased donor liver transplant recipients. Liver Transpl. 2009;15(11):1473–1480.
   PubMed Web of Science ®Google Scholar
• Jain A, Venkataramanan R, Hamad IS, et al. Pharmacokinetics of mycophenolic acid after mycophenolate mofetil administration in liver transplant patients treated with tacrolimus. J Clin Pharmacol. 2001;41(3):268–276.
   PubMed Web of Science ®Google Scholar
• Shiba H, Wakiyama S, Futagawa Y, et al. Switching from tacrolimus to cyclosporine A to prevent primary biliary cirrhosis recurrence after living-donor liver transplantation. Int Surg. 2013;98(2):156–159.
   PubMed Web of Science ®Google Scholar
• Firpi RJ, Zhu H, Morelli G, et al. Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation. Liver Transpl. 2006;12(1):51–57.
   PubMed Web of Science ®Google Scholar
• Trotter JF, Stolpman N, Wachs M, et al. Living donor liver transplant recipients achieve relatively higher immunosuppressant blood levels than cadaveric recipients. Liver Transpl. 2002;8(3):212–8.
   PubMed Web of Science ®Google Scholar
• Hibi T, Tanabe M, Hoshino K, et al. Cyclosporine A-based immunotherapy in adult living donor liver transplantation: accurate and improved therapeutic drug monitoring by 4-hr intravenous infusion. Transplantation. 2011;92(1):100–105.
   PubMed Web of Science ®Google Scholar
• Shinoda M, Tanabe M, Kawachi S, et al. Pharmacokinetics of mizoribine in adult living donor liver transplantation. Transplant Proc. 2012;44(5):1329–1335.
   PubMed Web of Science ®Google Scholar
• Takizawa D, Sato E, Hiraoka H, et al. Changes in apparent systemic clearance of propofol during transplantation of living related donor liver. Br J Anaesth. 2005;95(5):643–647.
   PubMed Web of Science ®Google Scholar
• Jin SJ, Jung JY, Noh MH, et al. The population pharmacokinetics of fentanyl in patients undergoing living-donor liver transplantation. Clin Pharmacol Ther. 2011;90(3):423–431.
   PubMed Web of Science ®Google Scholar